SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“Anti-HER2 therapies: what should clinicians focus on today?
Discover the key biological mechanisms behind anti-HER2 treatments and learn how to effectively manage therapy-related toxicities in clinical practice.
Join us and leading experts Tal Sella (IL) and Paola Zagami (IT), and don’t miss the opportunity to ask your questions during the QandA session moderated by Alexandru Eniu (CH).
When: Thursday 4 December 2025 – 18:00 CET
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
More posts featuring SPCC.